Company intelligence / Profile preview

Dr CADx

Ownership: Private
Development stage: Other

Overview

The company’s AI-powered diagnostic system for chest X-rays demonstrated a standalone accuracy of 96% for TB detection compared to the GeneXpert gold standard in pilot validation. For the other 14 chest findings tested so far, average accuracy was reported at 84%, comparable to expert radiologist performance. Clinical studies are ongoing and commercial launch was planned following completion of these studies[5].

Therapeutic areas: PulmonologyOncologyInfectious Diseases
Modalities: DeviceArtificial intelligence software (AI diagnostic platform)
Industry: Medical Imaging

Partnerships

Baobab Network accelerator program [5]

Beyond the preview

Go deeper on Dr CADx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dr CADx.

Explore the full profile